Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAAR) is a blank-check company focused on the domestic pharmaceutical manufacturing and life sciences sector. The company filed a Form 10-Q with the U.S. Securities and Exchange Commission on November 18, 2025, maintaining its public reporting obligations as an active registrant. DMAAR targets acquisition candidates in the U.S. drug manufacturing space, a sector that has drawn increased legislative and policy attention amid broader supply chain resilience efforts. For full sponsor details, IPO vintage, deal timeline, and historical filings on DMAAR, sign up for complete access at SpacDesk.